🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Road Scholarz A doctor in Chennai provided a closer look at the major reasons for denials. “It starts with spellings of names. If the spelling of the patient’s name in the CMCHIS card and Aadhaar card varies, it is immediately rejected. thehindu.com/sci-tech/healt…

Success happens slowly, then suddenly

What a privilege to be tired from work you once begged the universe for. what a privilege to feel overwhelmed by growth you used to dream about. what a privilege to be challenged by a life you created on purpose. what a privilege to outgrow things you used to settle for.

Distribution of IV fluids after infusion 💧💡 (Courtesy of The BMJ) #MedTwitter #MedEd #FOAMcc #MedX

AML Murali Super kind of you and Murali (who is anything but grumpy I suppose!) to say so.

Sajith Pai AML 😂 grumpy was meant to be a joke. Karthik Reddy and Sanjay Nath can testify to that :). Twitter was a different place 15+ years ago when picked this handle.

Murali Sajith Pai AML Sanjay Nath Snippet for Sajith Pai who's a sucker for snippets Murali was our Fund I legal advisor he was more like an energizer bunny though

Lenacapavir has been recommended by World Health Organization (WHO) for #HIV prevention this week. While this prevention medicine could be a game-changer in turning the tide on HIV epidemic, Gilead's licensing agreement will undermine broad access. Here's why 👇

Frugal Science “technologies illustrate how simple science tools, while being low key, tap into powerful scientific principles to execute vital processes typically reserved for costly labs.” #Science theindiaforum.in/science-and-te… The India Forum

CDSCO has flagged four drugs as spurious and 185 others as not of standard quality for June 2025. The list includes antibiotics and heart disease medications. Investigations are underway. #CDSCO #Drugs #MedicalStandard #Medicines Sanket Koul mybs.in/2eoa74J

The GLP-1 agonists marks a revolution in obesity treatment. Yet, like all revolutions, it comes with both promise and caution. The power of GLP-1 medications lie in responsible, informed use — not blind enthusiasm, write Bhavya Arora and Anoop Misra sciencechronicle.in/2025/07/19/the…

This is where healthcare is headed. Modelled on business that generates revenue in exponential ways. Maybe for a start, Goldman Sachs can agree that letting patients die isn’t such a great business prospect.

Just show up.

Success is the result of continuous effort.